Hepatitis C and Renal Transplantation in the Era of Modern Immunosuppression

Journal of the American Society of Nephrology

Volumn 14, Issue 11, 2003, Pages 2908-2918

  Abbott, Kevin C ^a,b   Bucci, Jay R ^a,b   Matsumoto, Cal S ^a,c   Swanson, S John ^a,c   Agodoa, Lawrence Y C ^d   Holtzmuller, Kent C ^a,b   Cruess, David F ^f   Peters, Thomas G ^a,c,e  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e UNIVERSITY OF FLORIDA HEALTH JACKSONVILLE   (United States)

^f Uniformed Serv Univ of Hlth Sci ^*

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ADULT; AGED; ARTICLE; CADAVER KIDNEY; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIALYSIS; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR; UNITED STATES;

EID: 0142184903     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000090743.43034.72     Document Type: Article

References (50)

1. Bucci JR, Matsumoto CS, Swanson SJ, Agodoa LY, Holtzmuller KC, Peters TG, Abbott KC: Donor hepatitis C seropositivity: Clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J Am Soc Nephrol 13: 2974-2982, 2002
2. Meier-Kriesche HU, Steffen BJ, Hochberg AM, Gordon RD, Liebman MN, Morris JA, Kaplan B: Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 27: 75:1341-1346, 2003
3. Schnitzler MA, Craig KE, Hardinger KE, Lowell JA, Brennan DC: Mycophenolate mofetil is associated with less death with function than azathioprine in cadaveric renal transplantation. Nephrol Dial Transplant 18: 1197-1200, 2003
4. Swanson SJ, Hypolite I, Oliver JD, Kirk AD, Ko CW, Agodoa LY, Peters TG, Abbott KC: Effect of donor factors on early graft survival in adult cadaveric kidney transplantation. Am J Transplant 2: 68-75, 2002
5. Ojo AO, Hanson JA, Meier-Kriesche H, Okechukwu CN, Wolfe RA, Leichtman AB, Agodoa LY, Kaplan B, Port FK: Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol 12: 589-597, 2001
6. Abbott KC, Hypolite IO, Hshieh P, Cruess D, Agodoa LY, Welch PG, Taylor AJ, Yuan CM: The impact of kidney transplantation on the incidence of congestive heart failure in patients with end-stage kidney disease due to diabetes. J Nephrol 14: 369-376, 2001
7. Meier-Kriesche HU, Kaplan B: Death after graft loss: A novel endpoint for kidney transplantation. Transplant Proc 33: 3405-3406, 2001
8. Mange KC, Joffe MM, Feldman HI: Effect of the use or nonuse of long-term dialysis on the subsequent survival of kidney transplants from living donors. N Engl J Med 344: 726-731, 2001
9. Natov SN: Transmission of viral hepatitis by kidney transplantation: Donor evaluation and transplant policies (part 1: hepatitis B virus). Transpl Infect Dis 4: 124-131, 2002
10. Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med 345: 41-52, 2001
11. Dragoni F, Mazzucconi MG, Cafolla A, Gentile G, Peraino M, Gonzalez M: Rapid liver failure related to chronic C hepatitis in an HIV seroposifive hemophilic patient with severe immunodepression. Haematologica 81: 335-338, 1996
12. Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, Myers RP, Muntenau M, Ratziu V, Manns M, Vogel A, Capron F, Chedid A, Bedossa P: A comparison of fibrosis progression in chronic liver diseases. J Hepatol 38: 257-265, 2003
13. Troppmann C, Rossaro L, Perez RV, McVicar JP: Early, rapidly progressive cholestatic hepatitis C reinfection and graft loss after adult living donor liver transplantation [Letter]. Am J Transplant 3: 239-240, 2003
14. Sulkowski MS, Thomas DL: Hepatitis C in the HIV-infected person. Ann Intern Med 138: 197-207, 2003
15. El-Serag HB, Anand B, Richardson P, Rabeneck L: Association between hepatitis C infection and other infectious diseases: A case for targeted screening? Am J Gastroenterol 98: 167-174, 2003
16. Everson GT: Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 8[10 Suppl 1]: S19-S27, 2002
17. Burroughs AK: Induction immunosuppression for patients who underwent transplantation for cirrhosis caused by hepatitis C? The answer is no! Liver Transpl 8[10 Suppl 1]: S47-S49, 2002
18. Eason JD, Nair S, Cohen AJ, Blazek JL, Loss GE Jr: Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 75: 1396-1399, 2003
19. Soguero C, Joo M, Chianese-Bullock KA, Nguyen DT, Tung K, Hahn YS: Hepatitis C virus core protein leads to immune suppression and liver damage in a transgenic murine model. J Virol 76: 9345-9354, 2002
20. Lauer GM, Ouchi K, Chung RT, Nguyen TN, Day CL, Purkis DR, Reiser M, Kim AY, Lucas M, Klenerman P, Walker BD: Comprehensive analysis of CDS(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol 76: 6104-6113, 2002
21. Shata MT, Anthony DD, Carlson NL, Andrus L, Brotman B, Tricoche N, McCormack P, Prince A: Characterization of the immune response against hepatitis C infection in recovered, and chronically infected chimpanzees. J Viral Hepat 9: 400-410, 2002
22. Kimball PM, Shiffman M: Hepatitis C viral peptides potentiate cyclosporine immunosuppression [Abstract 1093]. Am J Transplant 3: 431, 2003
23. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH: Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 15: 132: 296-305, 2000
24. Meier-Kriesche HU, Ojo A, Hanson J, Cibrik D, Lake K, Agodoa LY, Leichtman A, Kaplan B: Increased immunosuppressive vulnerability in elderly renal transplant recipients. Transplantation 69: 885-889, 2000
25. Meier-Kriesche HU, Kaplan B: Immunosuppression in elderly renal transplant recipients: Are current regimens too aggressive? Drugs Aging 18: 751-759, 2001
26. Morales JM, Campistol JM, Andres A, Dominguez-Gil B, Esforzado N, Munoz MA, Bruguera M, Oppenheimer F, Rodicio JL: Policies concerning the use of kidneys from donors infected with hepatitis C virus. Nephrol Dial Transplant. 15[Suppl 8]: 71-73, 2000
27. Everson GT: Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 8[10 Suppl 1]: S19-S27, 2002
28. Cornberg M, Hinrichsen H, Teuber G, Berg T, Naumann U, Falkenberg C, Zeuzem S, Manns MP: Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C. J Hepatol 37: 843-847, 2002
29. Firpi RJ, Nelson DR, Davis GL: Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection. Liver Transpl 9: 57-61, 2003
30. Smallwood GA, Davis L, Martinez E, Stieber AC, Heffron TG: Mycophenolate's influence in the treatment of recurrent hepatitis C following liver transplantation. Transplant Proc 34: 1559-1560, 2002
31. Fasola CG, Netto GJ, Jennings LW, Christensen LL, Molmenti EP, Sanchez EQ, Levy MF, Goldstein RM, Klintmalm GB: Recurrence of hepatitis C in liver transplant recipients treated with mycophenolate mofetil. Transplant Proc 34: 1563-1564, 2002
32. Langrehr JM, Neumann UP, Lang M, Muller AR, Jonas S, Settmacher U, Steinmuller T, Neuhaus P: First results from a prospective randomized trial comparing steroid-free induction therapy with tacrolimus and MMF versus tacrolimus and steroids in patients after liver transplantation for HCV. Transplant Proc 34: 1565-1566, 2002
33. Fasola CG, Netto GJ, Christensen LL, Molmenti EP, Sanchez EQ, Levy MF, Goldstein RM, Klintmalm GB: Delay of hepatitis C recurrence in liver transplant recipients: Impact of mycophenolate mofetil on transplant recipients with severe acute rejection or with renal dysfunction. Transplant Proc 34: 1561-1562, 2002
34. Hossain MM, Coull JJ, Drusano GL, Margolis DM: Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. Antiviral Res 55: 41-52, 2002
35. Margolis DM, Kewn S, Coull JJ, Ylisastigui L, Turner D, Wise H, Hossain MM, Lanier ER, Shaw LM, Back D: The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. J Acquir Immune Defic Syndr 31: 45-49, 2002
36. Sadek S, Medina J, Arias M, Sennesael J, Squiffiet JP, Vogt B: Short-term combination of mycophenolate mofetil with cyclosporine as a therapeutic option for renal transplant recipients: A prospective, multicenter, randomized study. Transplantation 74: 511-517, 2002
37. Batty DS Jr, Swanson SJ, Kirk AD, Ko CW, Agodoa LY, Abbott KC: Hepatitis C virus seropositivity at the time of renal transplantation in the United States: Associated factors and patient survival. Am J Transplant 1: 179-184, 2001
38. Meier-Kriesche HU, Ojo AO, Hanson JA, Kaplan B: Hepatitis C antibody status and outcomes in renal transplant recipients. Transplantation 72: 241-244, 2001
39. Pereira BJ, Natov SN, Bouthot BA, Murthy BV, Ruthazer R, Schmid CH, Levey AS: Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int 53: 1374-1381, 1998
40. Longenecker JC, Coresh J, Klag MJ, Levey AS, Martin AA, Fink NE, Powe NR: Validation of comorbid conditions on the end-stage kidney disease medical evidence report: The CHOICE study. Choices for Healthy Outcomes in Caring for ESRD. J Am Soc Nephrol 11: 520-529, 2000
41. Rigatto C, Foley R, Jeffery J, Negrijn C, Tribula C, Parfrey P: Electrocardiographic left ventricular hypertrophy in renal transplant recipients: Prognostic value and impact of blood pressure and anemia. J Am Soc Nephrol 14: 462-468, 2003
42. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347: 1557-1565, 2002
43. Hepatitis C virus transmission from an antibody-negative organ and tissue donor-United States, 2000-2002. MMWR Morb Mortal Wkly Rep 52: 273-276, 2003
44. Galel SA, Strong DM, Tegtmeier GE, Holland PV, Kuramoto IK, Kemper M, Pietrelli L, Gallarda J: Comparative yield of HCV RNA testing in blood donors screened by 2.0 versus 3.0 antibody assays. Transfusion 42: 1507-1513, 2002
45. Vrielink H, Reesink HW, van den Burg PJ, Zaaijer HL, Cuypers HT, Lelie PN, van der Poel CL: Performance of three generations of anti-hepatitis C virus enzyme-linked immunosorbent assays in donors and patients. Transfusion 37: 845-849, 1997
46. Barrera JM, Francis B, Ercilla G, Nelles M, Achord D, Darner J, Lee SR: Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sang 68: 15-18, 1995
47. Courouce AM, Bouchardeau F, Chauveau P, Le Marrec N, Girault A, Zins B, Naret C, Poignet JL: Hepatitis C virus (HCV) infection in haemodialysed patients: HCV-RNA and anti-HCV antibodies (third-generation assays). Nephrol Dial Transplant 10: 234-239, 1995
48. Alter MJ, Kuhnert WL, Finelli L, Centers for Disease Control and Prevention: Guidelines for laboratory testing and result reporting of antibody and hepatitis C virus. MMWR Recomm Rep 52(RR-3): 1-13, 2003
49. Feng S, Buell JF, Cherikh WS, Deng MC, Hanto DW, Kauffman HM, Leichtman AB, Lorber MI, Maters RG, McBride MA, Metzger RA, Nolte FS, O'Connor KJ, Roth D, Terrault NA, Henry ML: Organ donors with positive viral serology or malignancy: Risk of disease transmission by transplantation. Transplantation 74: 1657-1663, 2002
50. Schnitzler MA, Whiting JF, Brennan DC, Lin G, Chapman W, Lowell J, Boxerman S, Hardinger KL, Kalo Z: The expanded criteria donor dilemma in cadaveric renal transplantation. Transplantation 75: 1940-1945, 2003